New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
05:47 EDTSTJSt. Jude Medical announces preliminary results from EnligHTN III study
St. Jude Medical announced preliminary results from the EnligHTN III study, which found the company’s second-generation EnligHTN renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. Results from the EnligHTN I, II and III trials presented during EuroPCR add to the growing body of clinical evidence supporting the benefits of EnligHTN renal denervation technologies.
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
10:00 EDTSTJOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Best Buy (BBY) upgraded to Outperform from Market Perform at Telsey Advisory... BlackRock (BLK) upgraded to Outperform from Market Perform at Bernstein... Cerner (CERN) upgraded to Outperform from Market Perform at Cowen... Community Health (CYH) upgraded to Outperform from Market Perform at Raymond James... Lockheed Martin (LMT) upgraded to Neutral from Sell at UBS... Teekay Offshore Partners (TOO) upgraded to Buy from Neutral at Citigroup... Trinity Industries (TRN) upgraded to Buy from Neutral at Longbow... Zebra Technologies (ZBRA) upgraded to Overweight from Neutral at JPMorgan... Ross Stores (ROST) upgraded to Hold from Sell at Maxim... St. Jude Medical (STJ) upgraded to Outperform from Market Perform at Cowen... Wolverine World Wide (WWW) upgraded to Buy from Neutral at DA Davidson... D.R. Horton (DHI) upgraded to Market Perform from Underperform at Raymond James... KB Home (KBH) upgraded to Market Perform from Underperform at Raymond James... Sony (SNE) upgraded to Overweight from Neutral at JPMorgan.
09:29 EDTSTJSt. Jude Medical upgraded to Outperform at Cowen
As reported previously, Cowen upgraded St. Jude Medical to Outperform from Market Perform following positive results on its CardioMEMS HF monitoring system, which should support a return to 5% organic constant currency growth. Price target raised to $73 from $66.
07:49 EDTSTJSt. Jude Medical upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
November 18, 2014
17:19 EDTSTJSt. Jude Medical: CHAMPION clinical trial shows reduction in readmission rates
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use